Meeting
2013 ASCO Annual Meeting
Randomized phase II trial of extended versus standard neoadjuvant therapy for esophageal cancer, NCCTG (Alliance) trial N0849.
Authors
Steven R. Alberts
Mayo Clinic, Rochester, MN
Steven R. Alberts , Gamini S. Soori , Qian Shi , Dennis A. Wigle , Robert P. Sticca , Robert Clell Miller , James L. Leenstra , Patrick J. Peller , Tsung-Teh Wu , Harry H. Yoon , Timothy F. Drevyanko , Stephen Ko , Bassam Ibrahim Mattar , Daniel A. Nikcevich , Robert J. Behrens , Maged F. Khalil , George P. Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT00938470
Citation
J Clin Oncol 31, 2013 (suppl; abstr 4026)
DOI
10.1200/jco.2013.31.15_suppl.4026
Abstract #
4026
Poster Bd #
18
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma.
First Author: Ning Li
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).
First Author: Hiroyuki Arai
Poster
2021 ASCO Annual Meeting
Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma.
First Author: Hongli Li
Poster
2021 ASCO Annual Meeting
MONEO: A phase II study of avelumab (Av) plus FLOT in the peri-operative treatment for patients (pts) with resectable gastric or gastroesophageal junction cancer (GC).
First Author: MARIA ALSINA